B[What are the main considerations for the biomedical technologies to be added? Ministry of Commerce's response] On October 16, the spokesperson of the Ministry of Commerce answered reporters' questions on the revision of the "China's Catalog of Export Prohibited and Restricted Technologies". Q: What are the main considerations for the biomedical technologies to be added?
Answer: There are already some biomedical technologies in the current "Catalogue". This time, it is planned to add 5 technologies related to pathogenic microorganisms, cell and gene therapy, and small nucleic acid drugs. The main considerations are as follows:
The first is to safeguard human life, health and safety. Pathogenic microbial technologies are directly related to human health and national biosecurity. Including them in the Catalog and prohibiting their export is an institutional arrangement to safeguard national security and build a biosecurity barrier. It is also an objective need to protect the health of all mankind.
The second is to support China’s biomedical technology to carry out international cooperation in an orderly manner in accordance with laws and regulations. The listing of biomedical technologies this time will exclude or apply convenient measures to important situations of international cooperation. For example, export situations such as external authorization and licensing of relevant technology and process platforms with independent intellectual property rights, and use of relevant technology and processes to provide outsourced R&D and production services are not included in the scope of management; for relevant target discovery and verification technologies with independent intellectual property rights, exports through external authorization and licensing will be subject to convenient measures such as automatic licensing.
The third is to implement the concept of a human health community. This policy clearly stipulates that for exports of restricted technologies that are required for public health emergencies, humanitarian relief, use of overseas resources for joint research and development, etc., convenient measures such as automatic licensing are applicable. China will continue to share its technological development achievements with other countries around the world and make positive contributions to improving human health and well-being. A[The Ministry of Commerce and the Ministry of Science and Technology plan to revise the "China's Catalog of Prohibited and Restricted Export Technologies" and add some artificial intelligence, biomedicine, and photovoltaic technologies] October 16th, in accordance with the "Foreign Trade Law of the People's Republic of China" and the "People's Republic of China Technology Import and Export Administration Regulations", the Ministry of Commerce and the Ministry of Science and Technology plan to revise the "China's Export Prohibited and Restricted Technologies Catalog" to add some artificial intelligence, biomedicine, and photovoltaic technologies. Upon approval, it is now open to the public for solicitation of opinions, and pre-export registration management of related technologies will be implemented simultaneously.
This public solicitation of opinions involves 40 technologies in three fields: artificial intelligence, biomedicine, and photovoltaics. The field of artificial intelligence includes 23 technologies related to large models, agents, computing power clusters, and information processing; technologies that have entered the public domain through open source, published academic papers, etc. are not included in the scope of management. The field of biomedicine includes five technologies related to cell and gene therapy, small nucleic acid drugs, and pathogenic microorganisms; for external authorization models that do not involve ownership transfer, convenient measures such as automatic licensing are applicable. The photovoltaic field includes 12 technologies related to polysilicon manufacturing, silicon wafer manufacturing, and battery manufacturing; the scope of technical management also includes key and core equipment carrying related technologies. B[Inner Mongolia: The output value of the biomanufacturing industry will reach more than 100 billion yuan by 2030] On September 11, the General Office of the People's Government of the Inner Mongolia Autonomous Region recently issued the "Action Plan for Accelerating the High-quality Development of the Biomanufacturing Industry in the Inner Mongolia Autonomous Region." It is proposed that by 2030, the scale of the bio-manufacturing industry will continue to expand, the entire industry chain will be gradually built, and it will become an important engine for the development of new productivity in the autonomous region. The output value will reach more than 100 billion yuan, and the number of bio-manufacturing enterprises in the region will be strived to reach more than 500, among which, enterprises above designated size will reach To more than 200 companies, Hutong Chiba Bio-manufacturing Industry Cluster will be supported to create a national-level advanced manufacturing cluster; scientific and technological innovation capabilities will be significantly enhanced, and an important national bio-manufacturing technology innovation node will be basically established. The world's largest lactic acid bacteria and other microbial germplasm resources and genome database will be built to consolidate Traditional advantages include maintaining the international leading level in key indicators such as amino acid fermentation efficiency and veterinary vaccine research and development; industrial upgrading is accelerated, industrialization of key materials such as polylactic acid and bio-based nylon is realized, and the application proportion of non-grain raw materials is gradually increased; market entities and brand cultivation systems are accelerated to build 2- 3 local leading enterprises with a revenue of 5 billion yuan, more than 1 national-level specialized, special and new "little giant" enterprises, more than 5 autonomous region-level specialized, special and new small and medium-sized enterprises, and 2-3 brand products with strong competitiveness in the domestic market, introduce more than 2 well-known domestic and foreign companies to set up production bases. B[China takes the lead in formulating the world's first international standard for pathogenic gene databases] September 2nd, reporters learned from the National Standards Committee today that the world's first international standard for pathogenic gene databases, led by China, has been formally established recently. It will establish a unified "standard" for the construction of global pathogenic microorganism genome databases. The pathogenic microorganism genome reference database is equivalent to a genetic reference dictionary. By comparing the genetic information in the patient sample with the entries in this dictionary, you can identify which virus or bacteria it is, and doctors can treat it accordingly.
This time, the international standard led by China is to compile this "pathogen gene dictionary" for the world. After the standard is implemented, the unified database can accurately identify difficult infection cases and greatly reduce the probability of misdiagnosis and missed diagnosis. At the same time, it can help countries quickly identify the source of the epidemic, track the transmission path, and provide standardized and reliable technical support for epidemic prevention and control. (CCTV Finance)
— All loaded —
